



## Press Release

### New Chairmanship and New Mandates on the Advisory Board of MiP Pharma Group

**Homburg, September 1, 2025 –MiP Pharma Group has restructured its advisory board and expanded the panel with distinguished experts from the pharmaceutical and financial sectors. With these new appointments, the company is setting a course for sustainable development and the successful implementation of its strategic growth objectives.**

New members appointed to the advisory board include:

**Dr. Christiane Hanke-Harloff**, a biologist and experienced pharmaceutical and biotech manager. She brings extensive expertise in corporate development, change management, and the development and commercialization of innovative medicines and generics. Her career includes positions at Gilead Sciences, Jerini AG, Santen Pharmaceuticals, and Gedeon Richter.

**Gabriele Kreis-Schiemann**, a graduate in business administration. After working as a certified auditor and tax consultant, she has been active in interim management as a finance executive since 2004. She has many years of experience in corporate planning, change management, and finance, having held roles such as CFO, CEO, and finance director across various industries.

Additionally, **Alexander Zamora**, partner at capiton AG and head of the Healthcare & Life Sciences focus sector, has taken over as chair of the advisory board of the MiP Pharma Group.

With the new composition, MiP Pharma relies on a strong blend of pharmaceutical expertise, management competence, and financial know-how. The goal is to support the company's strategic development and further strengthen MiP Pharma's position as a reliable partner for hospitals, specialists such as urologists, general practitioners, and dentists, as well as its regional presence in Saarland.

### About MiP Pharma Group

The MiP Pharma Group distributes prescription generics, primarily antibiotics, over-the-counter medicines, and medical devices. Its main markets are Germany and Poland, as well as several other Eastern European countries. The company's sales focus is on the hospital sector and targeted specialist physician groups. With over 150 employees and around 400 drug approvals, MiP Pharma generates annual sales of approximately 50 million euros. Since November 2020, the formerly family-owned MiP Pharma has been a portfolio company of the Berlin-based financial investor capiton AG.

### Media Contact

Evelyn Back

0176 63613964

[buero@evelynback.com](mailto:buero@evelynback.com)

